Back to Results
First PageMeta Content
Epigenomics / Methylation / DNA methylation / Hypomethylating agent / Acute myeloid leukemia / Cellular differentiation / Genetics / Biology / Epigenetics


Abstract No[removed]Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML) Simone Jueliger1,
Add to Reading List

Open Document

File Size: 1,03 MB

Share Result on Facebook

City

Dublin / Berlin / San Francisco / Cambridge / /

Company

Pietro Taverna3 1Astex Pharmaceuticals / Epigenomics AG / Astex Pharmaceuticals Inc / Astex Pharmaceutical / 3Astex Pharmaceuticals / /

Country

Germany / United Kingdom / /

Event

FDA Phase / /

IndustryTerm

discovery technology / /

MedicalCondition

cancer / different cancers / diverse cancer / Acute Myeloid Leukaemia / different cancer / sensitive and resistant cancer / /

Product

SGI-110 / SGI110 / /

ProvinceOrState

California / /

Technology

DNA Chip / Hybridization / discovery technology / /

URL

www.astx.com / /

SocialTag